Churg-Strauss Syndrome clinical trials
The registry lists 61 studies for Churg-Strauss Syndrome across more than 10 countries. 17 are recruiting or about to start. 34 of them are mainly about Churg-Strauss Syndrome (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-13.
Get an email when these change. Save the Churg-Strauss Syndrome studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
University of Pennsylvania (7) · GlaxoSmithKline (6) · Assistance Publique - Hôpitaux de Paris (6) · University of South Florida (4) · AstraZeneca (4) · University of Oxford (2) · European EGPA Study Group (2) · Imperial College London (2)
What is being tested here
Drugs under test in Churg-Strauss Syndrome studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Benralizumab | 2 | 3 | 3 |
| Mepolizumab | 1 | 3 | 7 |
| SHR-1703 | 1 | 1 | 1 |
| Rituximab | 0 | 2 | 4 |
| Azathioprine | 0 | 1 | 2 |
| Povetacicept | 0 | 0 | 1 |
| Depemokimab | 0 | 1 | 1 |
| Tezepelumab | 0 | 0 | 1 |
| Vitamin D | 0 | 0 | 1 |
| Cyclophosphamide | 0 | 0 | 1 |
Drug classes tested here Antimetabolites 3
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
All 3
- Dec 2026Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With Polyangiitis · NS Pharma, Inc.
- Dec 2026Ocular Manifestations of Granulomatosis With Polyangiitis. · Military Institute od Medicine National Research Institute
- Feb 2027Benralizumab Effectiveness in EGPA · European EGPA Study Group
Who these studies take
Of the 14 Churg-Strauss Syndrome studies recruiting now, 11 (79%) set no upper age limit and 3 (21%) stop at 75 or younger. 7 (50%) take children under 18. 1 (7%) are for women only and 0 (0%) for men only; 3 (21%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 7 (50%) | 7 (50%) |
| 18 | 13 (93%) | 12 (86%) |
| 30 | 12 (86%) | 11 (79%) |
| 40 | 12 (86%) | 11 (79%) |
| 50 | 12 (86%) | 11 (79%) |
| 65 | 11 (79%) | 11 (79%) |
| 75 | 11 (79%) | 11 (79%) |
| 85 | 11 (79%) | 11 (79%) |
Across all 61 studies, recruiting or not: 13% stop at 75 or younger and 10% at 65; 20% take children; 3% are for women only and 0% for men only; 8% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
Studies
Recruiting first, then most recently updated. Showing 50 of 61. Browse all 61 → or search them.
- Roll-over Study for Participants Who Have Completed a Previous Clinical Study With Benralizumab (Fasenra) and Benefit From Continued TreatmentRecruitingNCT07444567Phase 314 countries
- A Trial to Investigate Benralizumab in Children With Eosinophilic DiseasesRecruitingNCT06512883Phase 310 countries
- Benralizumab Effectiveness in EGPARecruitingNCT078158861 country
- Longitudinal Study for Eosinophilic Granulomatosis With PolyangiitisRecruitingNCT003153805 countries
- Ocular Manifestations of Granulomatosis With Polyangiitis.RecruitingNCT076647091 country
- Vasculitis Pregnancy RegistryRecruitingNCT025935651 country
- Clinical Transcriptomics in Systemic Vasculitis (CUTIS)RecruitingNCT030043262 countries
- VCRC Tissue RepositoryRecruitingNCT029670682 countries
- One-Time DNA Study for VasculitisRecruitingNCT012413053 countries
- Beyond EOsinophils: proteoMICS to Identify Potential Biomarker of Organ Damage and Response to MEPOLIZUMAB in EGPAEnrolling by invitationNCT07343661Phase 41 country
- The Use of Machine Learning Techniques for the Differential Diagnosis Between Eosinophilic Granulomatosis With Polyangiitis and Hypereosinophilic SyndromeRecruitingNCT07275190Not applicable1 country
- A Study to Evaluate the Efficacy and Safety of SHR-1703 in Subjects With Eosinophilic Granulomatosis With Polyangiitis （EGPA）RecruitingNCT05979051Phase 2/31 country
- Eosinophil Subpopulations in Eosinophilic-associated DiseasesNot yet recruitingNCT06911775
- eGPA and Local Inflammation Within the Ear, Nose and Throat AreaRecruitingNCT062984481 country
- The Epigenomic Signature of Eosinophilic Granulomatosis With PolyangiitisNot yet recruitingNCT06231498
- Pediatric Vasculitis InitiativeRecruitingNCT020061347 countries
- Prospective Registry of Eosinophilia With Respiratory Manifestations With Translational Research Identifying and Characterizing EosinophilsRecruitingNCT045389371 country
- Efficacy and Safety of Benralizumab in EGPA Compared to Mepolizumab.Active, not recruitingNCT04157348Phase 39 countries
- Long-Term Safety and Effectiveness of Mepolizumab 300 mg in Europe (Mepo LTF Study)CompletedNCT075917531 country
- An Open-label Study of Povetacicept in Autoantibody-Associated Glomerular DiseasesActive, not recruitingNCT05732402Phase 1/24 countries
- Study of Mepolizumab-based Regimen Compared to Conventional Therapeutic Strategy in Patients With Eosinophilic Granulomatosis With Polyangiitis (E-merge)CompletedNCT05030155Phase 31 country
- Soluble CD95 Ligand Role in the Pathophysiology of Antineutrophil Cytoplasmic Antibody (ANCA) Associated VasculitisCompletedNCT03698071Not applicable1 country
- Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA)Active, not recruitingNCT05263934Phase 318 countries
- Retrospective Analysis of Systemic Glucocorticoid Mediated Long-term Effects, Patient Pathways and Economic Burden Across Multiple IndicationsCompletedNCT064887031 country
- Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With PolyangiitisActive, not recruitingNCT06046222Phase 28 countries
- Effectiveness on Sino-Nasal Symptoms Of Mepolizumab 300CompletedNCT075921041 country
- Explore the Efficacy and Mechanism of Action of Tezepelumab in Eosinophilic Granulomatosis With PolyangiitisActive, not recruitingNCT06230354Phase 21 country
- Hydroxychloroquine in ANCA Vasculitis EvaluationTerminatedNCT04316494Phase 41 country
- NUCALA® Special Drug Use Investigation (EGPA, Long-term)CompletedNCT035570601 country
- FASENRA Regulatory Postmarketing Surveillance in KoreaCompletedNCT050913331 country
- Low Dose Naltrexone to Improve Physical Health in Patients With VasculitisCompletedNCT03482479Phase 22 countries
- Rituximab in Eosinophilic Granulomatosis With PolyangiitisCompletedNCT02807103Phase 31 country
- Maintenance of Remission With Rituximab Versus Azathioprine for Newly-diagnosed or Relapsing Eosinophilic Granulomatosis With Polyangiitis.CompletedNCT03164473Phase 31 country
- Association Corticosteroid/Azathioprine in Microscopic Polyangiitis/ Polyarteritis Nodosa or Eosinophilic Granulomatosis With Polyangiitis (Churg Strauss Syndrome)CompletedNCT00647166Phase 31 country
- Identification of Autoantigens in EGPA and Severe Eosinophilic AsthmaCompletedNCT046714461 country
- Mepolizumab Long-term Study to Assess Real World Safety and Effectiveness of Eosinophilic Granulomatosis With Polyangiitis (EGPA) in JapanCompletedNCT045519891 country
- Long-term Access Program (LAP) of Mepolizumab for Subjects Who Participated in Study MEA115921CompletedNCT03298061Phase 37 countries
- Urinary T Lymphocytes Predict Renal Flares in Patients With Inactive ANCA-associated GlomerulonephritisCompletedNCT044283981 country
- Eosinophilic Granulomatosis With Polyangiitis CohortCompletedNCT030366701 country
- PRagmatic Analysis of Vitamin D in ANCA-Associated VasculitisCompletedNCT04280601Not applicable1 country
- Urinary T Cell Biomarker for Prediction in ANCA GlomerulonephritisStatus unknownNCT043206672 countries
- Anti-Interleukin-5 (IL-5) Study for Hypereosinophilic SyndromeCompletedNCT00266565Phase 1/21 country
- VCRC Patient Contact Registry Patient-Reported Data Validation StudyCompletedNCT021909421 country
- Journey of Patients With Vasculitis From First Symptom to DiagnosisCompletedNCT034102901 country
- A Study to Investigate Mepolizumab in the Treatment of Eosinophilic Granulomatosis With PolyangiitisCompletedNCT02020889Phase 39 countries
- Immuno-ablation With Chemoimmunoradiation and Autologous Stem Cell Transplant for Churg-Strauss SyndromeTerminatedNCT02728271Early Phase 1
- The ANCA Vasculitis Questionnaire (AAV-PRO©)CompletedNCT025070241 country
- Mepolizumab As a Steroid-sparing Treatment Option in the Churg Strauss SyndromeCompletedNCT00527566Phase 1/21 country
- American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Diagnostic and Classification Criteria for Primary Systemic VasculitisStatus unknownNCT0106620833 countries
- Abatacept in ANCA Associated VasculitisTerminatedNCT00482066Phase 21 country